IBOGF (Universal Ibogaine) Retained Earnings: $-19.96 Mil (As of Apr. 2025)


What is Universal Ibogaine Retained Earnings?

Universal Ibogaine IBOGF -1.07% Retained Earnings is $-19.96 Mil as of Apr. 2025.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Universal Ibogaine's retained earnings for the quarter that ended in Apr. 2025 was $-19.96 Mil.

Universal Ibogaine's quarterly retained earnings increased from Oct. 2024 ($-20.01 Mil) to Jan. 2025 ($-19.35 Mil) but then declined from Jan. 2025 ($-19.35 Mil) to Apr. 2025 ($-19.96 Mil).

Universal Ibogaine's annual retained earnings declined from Jul. 2022 ($-17.58 Mil) to Jul. 2023 ($-19.02 Mil) and declined from Jul. 2023 ($-19.02 Mil) to Jul. 2024 ($-19.82 Mil).


Universal Ibogaine  (OTCPK:IBOGF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Universal Ibogaine Retained Earnings Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Retained Earnings Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Retained Earnings
Get a 7-Day Free Trial -0.45 -0.73 -17.58 -19.02 -19.82

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.33 -19.82 -20.01 -19.35 -19.96

Universal Ibogaine Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-19.96 Mil mean?
Universal Ibogaine (IBOGF) has a Retained Earnings of $-19.96 Mil as of Apr. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Retained Earnings too high?
Universal Ibogaine's current Retained Earnings is $-19.96 Mil.
How does Universal Ibogaine's Retained Earnings compare to LABT and CALC?
Universal Ibogaine's Retained Earnings of $-19.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Retained Earnings is $-19.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Retained Earnings of $-19.96 Mil. The current Retained Earnings is $-19.96 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Retained Earnings is $-19.96 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.